Crucell N.V. has entered a non-exclusive STAR research license agreement with Invitrogen Corp.’s PD-Direct Bioprocess Services. The license covers the production of monoclonal antibodies.

According to Crucell, STAR technology is useful for the production of recombinant human antibodies and proteins. It has a potentially broad application and is effective for production of antibodies and proteins on mammalian cell lines such as Crucell’s PER.C6 human cell technology. The technology has the potential to reduce production costs by increasing production yields.